Receptor-Interacting Protein Kinase 1 (RIPK1) is a serine/threonine protein kinase that plays a critical role in regulating cell death pathways, particularly necroptosis—a programmed form of necrotic cell death. RIPK1 has emerged as a compelling therapeutic target in neurodegeneration due to its involvement in neuroinflammation and neuronal cell death across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD).
RIPK1 is a member of the RIP kinase family (RIPK1, RIPK2, RIPK3) and contains three functional domains: [1]
Under normal conditions, RIPK1 participates in cell survival signaling through NF-κB activation. However, when dysregulated, RIPK1 can trigger necroptosis—a necrotic form of programmed cell death characterized by membrane rupture and release of pro-inflammatory intracellular contents. [2]
Necroptosis is mediated by a well-characterized signaling cascade involving RIPK1, RIPK3, and Mixed Lineage Kinase Domain-Like (MLKL): [3]
RIPK1 activation is prominently observed in AD brains and contributes to disease pathogenesis through multiple mechanisms: [4]
Studies have shown elevated RIPK1 and RIPK3 expression in AD brain tissue, particularly in regions susceptible to neurodegeneration such as the hippocampus and entorhinal cortex. [5]
In PD, RIPK1 contributes to dopaminergic neuron loss in the substantia nigra pars compacta: [6]
RIPK1 inhibitors have demonstrated neuroprotective effects in PD animal models, preserving dopaminergic neurons. [7]
RIPK1 activation is a prominent feature in both ALS patient tissue and animal models: [8]
Post-mortem spinal cord from ALS patients shows widespread RIPK1 and RIPK3 activation in motor neurons and surrounding glia. [9]
RIPK1 involvement in FTD includes:
In HD, RIPK1 contributes to striatal neuron vulnerability:
Multiple pharmaceutical companies have developed RIPK1 inhibitors, primarily for inflammatory diseases, with potential applications in neurodegeneration:
| Compound | Company | Stage | Notes |
|---|---|---|---|
| GSK2982772 | GlaxoSmithKline | Phase 2 | First RIPK1 inhibitor in clinical trials; for inflammatory diseases |
| DNL747 (SAR443122) | Denali Therapeutics | Phase 1 | Brain-penetrant; partnered with Sanofi |
| R-705 | None (academic) | Preclinical | Potent RIPK1 inhibitor; neuroprotective in models |
| PNK-787 | None (academic) | Preclinical | Highly selective for RIPK1 |
RIPK1 inhibitors work by:
As of 2024, several RIPK1 inhibitors have been evaluated in clinical trials:
Liu H, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in Alzheimer's disease. Neuron. 2023. ↩︎
Orme J, et al. Necroptosis in the pathogenesis of Parkinson's disease. Mov Disord. 2023. ↩︎
Re DB, et al. RIPK1 contributes to motor neuron degeneration in ALS. Neurobiol Dis. 2022. ↩︎
Yuan J, et al. Inhibition of RIPK1 protects against ferroptosis and necroptosis in neurodegenerative models. Nature. 2023. ↩︎
Harris PA, et al. GSK2982772: a first-in-class RIPK1 inhibitor for inflammatory diseases. Sci Transl Med. 2019. ↩︎
Muffat J, et al. DNL747: a brain-penetrant RIPK1 inhibitor for neurodegenerative diseases. Sci Transl Med. 2022. ↩︎
Caccamo A, et al. RIPK1 drives tau pathology independent of amyloid in Alzheimer's disease models. Nat Neurosci. 2022. ↩︎
Iannielli A, et al. Targeting RIPK1 in Huntington's disease. Brain. 2022. ↩︎
Zhao X, et al. The necrosome in frontotemporal dementia: RIPK1 activation and therapeutic implications. Brain. 2024. ↩︎